Announcement Summary

Entity name

MAYNE PHARMA GROUP LIMITED

Announcement Type

New announcement

Date of this announcement

Tuesday October 07, 2025

Details of +securities that have ceased

ASX +security code	Security description	Number of +securities that have ceased	The +securities have ceased due to	Date of cessation
MYXAN	PERFORMANCE RIGHTS	529,129	Expiry of option or other convertible security without exercise or conversion	30/09/2025
MYXAT	OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	695,322	Expiry of option or other convertible security without exercise or conversion	30/09/2025

Refer to next page for full details of the announcement

Part 1 - Announcement Details

1.1 Name of +Entity

MAYNE PHARMA GROUP LIMITED

We (the entity named above) provide the following information about our issued capital.

1.2 Registered Number Type	**Registration Number**
ABN	76115832963

1.3 ASX issuer code

MYX

1.4 The announcement is

New announcement

1.5 Date of this announcement

7/10/2025

Part 2 - Details of +equity securities or +debt securities that have ceased

ASX +Security Code and Description

MYXAT : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES

Unquoted +equity securities that have ceased

Number of securities that have ceased

695,322

Reason for cessation

Expiry of option or other convertible security without exercise or conversion

Date of cessation

30/9/2025

Is the entity paying any consideration for the cessation?

No

Any other information the entity wishes to notify to ASX about the cessation?

Options issued in 2020 which did not meet the vesting conditions and subsequently expired. These options would have lapsed in connection with the Scheme had the Scheme been implemented prior to the expiry date (refer section 11.3(a) of the Scheme Booklet).

ASX +Security Code and Description

MYXAN : PERFORMANCE RIGHTS

Unquoted +equity securities that have ceased

Number of securities that have ceased

529,129

Reason for cessation

Expiry of option or other convertible security without exercise or conversion

Date of cessation

30/9/2025

Is the entity paying any consideration for the cessation?

No

Any other information the entity wishes to notify to ASX about the cessation?

Performance Rights issued in 2020 which did not meet the vesting conditions and subsequently expired. These options would have lapsed in connection with the Scheme had the Scheme been implemented prior to the expiry date (refer section 11.3(b) of the Scheme Booklet).

Part 3 - Issued capital following changes

Following the cessation of the +securities the subject of this notification, the issued capital of the entity will comprise:

The figures in parts 3.1 and 3.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

3.1 Quoted +equity securities and +debt securities (total number of each +class of +securities quoted on ASX)

ASX +security code and description	Total number of +securities on issue
MYX : ORDINARY FULLY PAID	81,245,827

3.2 Unquoted +equity securities (total number of each +class of +equity securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
MYXAA : CONVERTIBLE NOTES	27,950
MYXAN : PERFORMANCE RIGHTS	5,358,302
MYXAT : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	0

Note: the figures stated in the tables above are used to calculate the total market capitalisation of the entity published by ASX from time to time. The table will not include those classes of +securities that have ceased or lapsed in their entirety in ASX records before the announcement date described in Q1.5, even if the entity has advised ASX of a change to that class of +security in Part 2 of this form.